The neoplastic transforming function of the SV40 large T antigen (T) and the adenoviral E1A product(s) depends, in part, upon binding by T/E1A to a series of cellular proteins, two of which, pRB and p53 [binds to T only], are known tumor suppressor gene products. The results of genetic analyses strongly suggest that, in the case of pRB-T binding, T dominates pRB and perturbs one or more aspects of its growth suppression function. This application will focus on another cellular protein which also binds to T and E1A-p107. Genetic analyses indicate that binding of this protein is also linked to the performance of T/E1A transforming function. Moreover, it and pRB, in part, interact physically with the same T and E1A sequences. A third protein, p300, is a known E1A binding element, and preliminary data suggest that it may bind to T as well. Again, genetic analyses strongly suggest a link between binding to these proteins and maintenance of their transforming function. Circumstantial evidence points to the possibility that p107 and p300 are also tumor suppressor gene products. The proposed experimental plan is aimed primarily at understanding how p107 and p300 function normally and how binding of two dominant DNA tumor viral oncogene products affects them.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA015751-19
Application #
3481718
Study Section
Virology Study Section (VR)
Project Start
1981-09-01
Project End
1996-08-31
Budget Start
1992-09-01
Budget End
1993-08-31
Support Year
19
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215